Protalix BioTherapeutics
PLX
28 hedge funds and large institutions have $15.5M invested in Protalix BioTherapeutics in 2016 Q2 according to their latest regulatory filings, with 2 funds opening new positions, 3 increasing their positions, 10 reducing their positions, and 7 closing their positions.
0.18% less ownership
Funds ownership: 2.6% → 2.43% (-0.18%)
15% less funds holding
Funds holding: 33 → 28 (-5)
27% less capital invested
Capital invested by funds: $21.2M → $15.5M (-$5.74M)
70% less repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 10
71% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 7
97% less call options, than puts
Call options by funds: $1K | Put options by funds: $36K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$38.4K |
| 2 |
VKH
Virtu KCG Holdings
New York
|
+$8.26K |
| 3 |
UBS Group
Zurich,
Switzerland
|
+$4.02K |
| 4 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
+$671 |
| 5 |
PCM
Prelude Capital Management
New York
|
+$80 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BC
Broadfin Capital
New York
|
-$1.09M |
| 2 |
VanEck Associates
New York
|
-$90K |
| 3 |
Barclays
London,
United Kingdom
|
-$51.8K |
| 4 |
PVH
Psagot Value Holdings
Tel Aviv,
Israel
|
-$50.5K |
| 5 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
-$37.5K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
ARTA
26
A.R.T. Advisors
New York
| – | -$18K | -2,221 | Closed |
|
|
PCM
27
Penserra Capital Management
Orinda,
California
| – | -$5.38K | -1,680 | Closed |
|
28
HSBC Holdings
London,
United Kingdom
| – | -$13K | -1,500 | Closed |
|
|
MMH
29
Menora Mivtachim Holdings
Ramat Gan,
Israel
| – | -$4K | -515 | Closed |
|
30
Simplex Trading
Chicago,
Illinois
| – | -$104 | -13 | Closed |
|
|
PCM
31
Prelude Capital Management
New York
| – | +$80 | +10 | New |
|
PLX Hedge Fund Activity: Q2 2016 in Review
28 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in Protalix BioTherapeutics (PLX) for Q2 2016, worth a combined $15.5M — down 27% from $21.2M a quarter earlier.
Sellers outnumbered buyers: 7 funds closed out of PLX and 2 opened new positions — a net loss of 5 holders — while 10 trimmed existing stakes and 3 added.
The largest buyer was Renaissance Technologies, adding an estimated $38.4K. The largest seller was Broadfin Capital, cutting an estimated $1.09M.
- 28 institutional investors held Protalix BioTherapeutics (PLX) as of Q2 2016, down from 33 in Q1 2016.
- Funds reported $15.5M of Protalix BioTherapeutics stock for Q2 2016, down 27% quarter-over-quarter.
- 2 funds opened new Protalix BioTherapeutics positions in Q2 2016 and 7 closed out, a net change of -5 holders.
- The largest Protalix BioTherapeutics buyer in Q2 2016 was Renaissance Technologies, an estimated $38.4K added.
- The largest Protalix BioTherapeutics seller in Q2 2016 was Broadfin Capital, an estimated $1.09M sold.
Based on aggregated 13F filings for Q2 2016.